Animal health firm Zoetis Inc. (NYSE:ZTS) on Thursday reported a fourth-quarter 2025 adjusted earnings per share of $1.48. The company beat the consensus of $1.40.
The company reported sales of $2.387 billion, up 3% year over year, almost in line with the consensus of $2.36 billion. On an organic operational basis, revenue increased 4%.
Adjusted net income was $648 million, an increase of 3% on a reported basis and 4% on an organic operational basis.
Adjusted net income for the fourth quarter of 2025 excludes the net impact of $45 million for purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.
Segment Breakdown
Revenue in the U.S. segment was $1.2 billion, a decrease of 2% on a reported basis and flat on an organic operational basis.
Sales of companion animal products decreased 1%.
A decline in the company’s monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs, and Solensia for cats, was partially offset by growth in the company’s …